Burning Rock Biotech Limited reported Q1 2026 revenues of RMB107.9 million, down 18.9% year-over-year, mainly due to fewer tests in its central lab and pharma R&D segments, and a one-off issue at two hospitals affecting in-hospital revenue. Despite the revenue drop, the company improved gross margin in its central lab business but saw declines in other segments. Operating expenses fell 14%, driven by cost controls, but the company still posted a net loss of RMB17.5 million. Cash reserves remain strong at RMB448.7 million. The company continues advancing its precision oncology technology and clinical validation efforts.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
